Subcutaneous Vitamin K is NOT Recommended for Mild Rectal Bleeding in Cirrhosis
Subcutaneous vitamin K should not be administered to this patient with hepatic cirrhosis and mild rectal bleeding, as it does not improve coagulation parameters or reduce bleeding risk in cirrhosis-related coagulopathy. 1
Why Vitamin K Doesn't Work in Cirrhosis
The elevated INR in cirrhosis reflects decreased hepatic synthesis of clotting factors, not vitamin K deficiency. The 2022 EASL guidelines explicitly state that vitamin K administration—particularly when given orally or subcutaneously—does not improve the INR in patients with chronic liver disease 1. This practice, while historically common, is not supported by evidence.
Key evidence:
- Saja et al. demonstrated that one subcutaneous dose of vitamin K did not modify coagulation parameters in cirrhosis patients 1
- A 2013 study of 89 patients across different stages of liver dysfunction showed that vitamin K administration did not affect measured coagulation parameters including Factor VII, protein C, or protein S 2
- Intravenous vitamin K can transiently correct INR only in cholestatic liver disease (where true vitamin K malabsorption exists), but this is a different pathophysiology 1
The Coagulopathy of Cirrhosis is Different
Patients with cirrhosis exist in a state of rebalanced hemostasis—they have both decreased procoagulant factors AND decreased anticoagulant factors. The INR of 1.7 in this patient:
- Does not predict bleeding risk 1, 3
- Reflects laboratory artifact more than true bleeding tendency
- Should not be "corrected" with vitamin K or fresh frozen plasma
Studies show no difference in INR between cirrhosis patients who bleed and those who don't 1.
What Should Be Done Instead
For mild rectal bleeding in this cirrhosis patient:
Identify the bleeding source: The rectal bleeding is likely related to:
- Portal hypertension (rectal varices, portal hypertensive gastropathy)
- Local anorectal pathology (hemorrhoids, fissures)
- NOT the elevated INR
Address the underlying cause:
- Endoscopic evaluation if indicated
- Local hemostatic measures for anorectal sources
- Portal hypertension management if varices present
Avoid unnecessary interventions:
Important Caveats
The only exception where vitamin K might have a role: If there is cholestatic liver disease (primary biliary cholangitis, primary sclerosing cholangitis, biliary obstruction) where true fat-soluble vitamin malabsorption exists, intravenous vitamin K may transiently improve INR 1. However, this patient has cirrhosis without mention of cholestasis.
The FDA label for vitamin K 4 indicates its use for "hypoprothrombinemia due to other causes" in adults with doses of 2.5-25 mg, but this applies to anticoagulant-induced or malabsorption-related coagulopathy—not cirrhosis-related synthetic dysfunction.
Bottom Line
Focus on treating the bleeding source, not the INR. The elevated INR is an expected laboratory finding in cirrhosis that does not require or respond to vitamin K correction when given subcutaneously.